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AMAROS = After Mapping of the Axilla: Radiotherapy or Surgery; ANLD = axillary lymph node dissection; EORTC = European Organization for
Research and Treatment of Cancer; MIND-ACT = Microarray in Node Negative Disease and Anthracycline Chemotherapy or Taxane; PCR = poly-
merase chain reaction; PFS = progression-free survival.
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Introduction
The European Organization for Research and Treatment of
Cancer (EORTC) Breast Cancer Group is currently
running eight studies: four randomised phase III trials,
three phase II trials and one survey. In 2003, the Breast
Cancer Group entered 1003 patients in these studies via
87 active participating centres. Table 1 presents a
summary of the current open studies. The two most
important studies will be reviewed here.
Another important trial that is in preparation and will be
open in the near future is the MIND-ACT trial: a
prospective, randomised study in node-negative breast
cancer patients with two aims. The first is to test the
performance of the gene prognosis signature (70-gene
classifier) in comparison with the common clinic–
pathologic criteria as a new prognostic tool that will
reduce the risk of overtreatment with the correct identifica-
tion of patients who need adjuvant chemotherapy. The
second aim is to evaluate a docetaxel + capecitabine
(nonanthracycline-based) regimen as a superior alternative
to an anthracycline-based regimen, for high-risk node-
negative breast cancer.
The EORTC 10981-22023 AMAROS trial
Until a few years ago an important part in staging breast
cancer patients was the axillary lymph node dissection
(ALND). Evidence has emerged that the sentinel node
biopsy procedure by lymphatic mapping is an equivalent
staging procedure to ALND [1–3]. The introduction of a
new surgical technique requires a process of quality-
controlled implementation (preferably by treating patients
in prospective studies) in order not to jeopardise, but to
improve the level of care gained by the ALND, as has been
achieved by the implementation of breast-conserving
surgery [4]. Only in this way can the questions regarding
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Abstract
The present clinical trial update consists of a review of two of eight current studies (the 10981-22023
AMAROS trial and the 10994 p53 trial) of the European Organization for Research and Treatment of
Cancer Breast Cancer Group, as well as a preview of the MIND-ACT trial. The AMAROS trial is
designed to prove equivalent local/regional control for patients with proven axillary lymph node
metastasis by sentinel node biopsy if treated with axillary radiotherapy instead of axillary lymph node
dissection, with reduced morbidity. The p53 trial started to assess the potential predictive value of p53
using a functional assay in yeast in patients with locally advanced/inflammatory or large operable
breast cancer prospectively randomised to a taxane regimen versus a nontaxane regimen.
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the importance of different technical aspects and the
questions on the clinical implications be answered.
The EORTC 10981-22023 AMAROS trial is a phase III
study comparing a complete ALND with radiotherapy to
the axilla in sentinel node-positive patients, whereas
sentinel node-negative patients are followed for the
endpoints of the study as well (Fig. 1). Patients enrolled on
the trial must have an operable invasive breast cancer
greater than 5 mm and less than 3 cm, without clinically
suspect regional lymph nodes. This intergroup study,
which first enrolled patients in February 2001, is
coordinated by the EORTC Breast Cancer Group in
collaboration with the EORTC Radiotherapy Group, the
BOOG (Breast Cancer Research Group) from The
Netherlands and, in the near future, with former Axillary
Lymphatic Mapping Against Nodular Axillary Clearance
centres from the UK.
The main objective of the trial is to prove equivalent
local/regional control for patients with proven axillary
lymph node metastasis by sentinel node biopsy if treated
with axillary radiotherapy instead of axillary lymph node
dissection, with reduced morbidity. A second objective is
to investigate whether adequate axillary control can be
obtained by not subjecting patients with a negative
sentinel lymph node to ALND.
As of 1 May, 18 institutes have included 1173 patients. It
is assumed that the axillary recurrence-free rate in the
ALND treatment group at 5 years equals 98%, and the
aim of this study is to show that the axillary recurrence-free
rate in the radiotherapy group at 5 years is not less than
96%. Given the ratio of 40 positive patients/60 negative
patients, a total of 3485 patients are required to complete
this study. The ratio to date of 35/63 (taking into account
a 2% nonidentification rate) leads to a slight adjustment of
the total number of patients needed. The study will at least
be continued up to 2006.
In order to ensure that the trial results are not
compromised by the use of improper techniques, or by a
Table 1
Current European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Group (BCG) trials
Total 
Required randomised/
Start number  of  registered  on
Trial number Study title date patients 1 April 2004
10981-22023 AMAROS study — After Mapping of the Axilla: Radiotherapy or Surgery 15 February 2001 3485 1133
10994 p53 study — first prospective intergroup translational research trial  14 March 2001 1440 863
assessing the potential predictive value of p53 using a functional assay in 
yeast in patients with locally advanced/inflammatory or large operable 
breast cancer prospectively randomised to a taxane regimen versus a 
nontaxane regimen (BIG number 00-01)
10995-16999 A randomised phase II study of CMF in combination with anti-cerbB2  5 February 2002 66 32
antibody (Herceptin®) in women with metastatic cancer
10001-160010 A randomised phase II trial evaluating the efficacy of capecitabine and  17 September 2002 72 38
vinorelbine in anthracycline and taxane pretreated metastatic breast cancer
10002 A survey of the BIG (BIG 03-98) to assess the attitude toward the risk of  5 May 2003 385 51
loss of fertility related to adjuvant therapies for patients with early breast 
cancer aged younger than 35 years
10011 HERA study — a randomised three-arm multicentre comparison of 1 year  BIG, December 2001;  4482 EORTC BCG,
and 2 years of Herceptin®, versus no Herceptin® in women with  EORTC, March 2002 143; total, 3555
HER2-positive primary breast cancer who have completed adjuvant 
chemotherapy (BIG 01-01/EORTC 10011)
10021 An EORTC randomised, double-blind, placebo-controlled, phase II  28 May 2003 108 2
multicentre trial of anastrozole (Arimidex) in combination with ZD1839 
(Iressa) or placebo in patients with advanced breast cancer
10031 SOFT trial — intergroup study IBCSG 24 02/BIG 2-02/EORTC 10031.  14 January 2004 3000 EORTC BCG, 0; 
A phase III trial evaluating the role of ovarian function suppression and the  total, 21
role of exemestane as adjuvant therapies for premenopausal women with 
endocrine-responsive breast cancer tamoxifen versus ovarian function 
suppression + tamoxifen versus ovarian function suppression + exemestane
BIG, Breast International Group; CMF, cyclophosphamide methotrexate and 5-fluorouracil; HERA, HERceptin® adjuvant; SOFT, Suppression of
Ovarian Function Trial; IBCSG, International Breast Cancer Study Group.167
large variation in the quality of the treatment techniques
used, the protocol provides guidelines for the sentinel
node biopsy procedure, the pathology, the surgery and
the radiotherapy. Quality assurance procedures were
initiated to guarantee a uniform quality of treatment
between institutions. The surgical quality control consists
of quality control before starting to include patients in the
trial, regular site visits and axillary failure analysis by the
Independent Data Monitoring Committee.
Before a centre is allowed to include patients in the
AMAROS trial, the quality of the sentinel node procedure
is checked. This requirement is based on the existence of
a learning curve [5–7]. The surgeon and nuclear physician
conducting the sentinel node procedure should have
followed a training course. The trial protocol demands a
so-called combined technique, using lymphoscintigraphy,
preoperative blue dye injection and peroperative use of a
gamma probe. At least 30 sentinel node procedures
followed by an ALND of at least level I and level II have to
be performed, with a minimum of 27 patients with
accurate sentinel node identification. Not more than one
false negative should be encountered. Besides inspection
of the learning curve by an onsite review of 30 original
patient files, the surgical quality control from the start
consists of witnessing a lymphoscintigraphy and sentinel
node biopsy procedure. So far 98% of the sentinel nodes
have been identified, suggesting that the quality control is
very effective. In addition, 63% of the sentinel node
biopsies resulted in a negative sentinel node, which
corroborates the superfluity of following axillary staging
operations in the past.
The EORTC Radiotherapy Group has a strong tradition of
institution-bound quality assurance [8–10]. Approval of
the dummy run by the Radiotherapy Quality Assurance
Committee is one of the prerequisites in the AMAROS
trial. A recent study of the compliance of participating
institutes to the radiotherapy guidelines of the AMAROS
dummy run protocol resulted in a number of potential
protocol deviations found at first assessment [11]. Since
recommendations led to a large number of adaptations by
the participants, a considerable improvement in protocol
compliance and inter-institutional consistency was
achieved.
The evaluation of disseminated breast tumour cells in
sentinel lymph nodes by quantitative real-time PCR and
the comparison of the sensitivity of this assay with the
routine histological analysis is part of the translational
research [12]. The quantitative real-time PCR assay with
multiple mRNA markers for the detection of disseminated
breast cancer cells in sentinel nodes resulted in an
upstaging of sentinel nodes containing metastastic
disease of 10% compared with the routine histological
analysis. The application of this technique may be of
clinical relevance, as it is suggested that micrometastatic
disease in sentinel nodes is associated with further nodal
nonsentinel node metastases in breast cancer.
More detailed information is available online (www.amaros.nl).
The EORTC 10994 p53 trial 
(Breast International Group 00-01)
The p53 study is the first prospective intergroup trans-
lational research trial assessing the potential predictive
value of p53 using a functional assay in yeast in patients
with locally advanced/inflammatory or large operable
breast cancer prospectively randomised to a taxane
regimen versus a nontaxane regimen. The EORTC Breast
Cancer Group, the sponsor of the trial, collaborates in this
trial with the Anglo-Celtic group, the SAKK (Swiss Group
for Clinical Research) group and the Swedish group. Free
drug supply (docetaxel) is offered by the pharmaceutical
industry partner Aventis. Furthermore, the trial is
supported by two grants from Aventis and Pfizer. Figure 2
depicts the scheme of the p53 study.
Factors predictive of the response to chemotherapy are
virtually nonexistent. Experimental and clinical studies have
shown that anticancer agents achieve their cytotoxic
effect through apoptosis [13] and that p53 is a key gene
in the apoptotic pathway. In vivo and in vitro data suggest
that p53-mutated tumours are resistant to anthracyclines
but remain sensitive to taxanes [14–20]. Limited clinical
data suggest that this finding may be true in patients with
breast cancer [21]. Unfortunately the immunohisto-
chemistry method is not the best method to assess p53.
There is a risk of false-negative and false-positive results
when p53 is assessed by the immunohistochemistry
method as compared with the sequencing method [22]. A
functional assay for p53 in yeast gives a direct information
regarding p53 function (detects biologically important
mutations) and is more sensitive than sequencing (it is
Available online http://breast-cancer-research.com/content/6/4/165
Figure 1
Treatment scheme of the European Organization for Research and
Treatment of Cancer 10981-22023 AMAROS trial. cN0, clinically
negative lymph nodes; SN, sentinel node.
Follow-up
SN-Negative
Axillary Lymph
Node Dissection
Radiotherapy
of the Axilla
SN-Positive
Sentinel Node Biopsy
Randomisation
0.5 < T < 3 cm cN0 Invasive breast cancer168
insensitive to contamination of samples with normal
tissue) [23].
In this study we are comparing prospectively a nontaxane
anthracycline-based regimen versus a taxane regimen. We
are using the p53 functional test in yeast. We are
performing this trial in the neoadjuvant setting, which allows
one to assess clinical and pathological responses after
chemotherapy. Patients with either large operable or locally
advanced cancers or inflammatory cancers are eligible.
The primary endpoints consist of comparison of the
progression-free survival (PFS) of patients who received
neoadjuvant chemotherapy without taxanes (treatment A)
with the PFS of patients who received a chemotherapy
with taxanes (treatment B), in both the normal p53
subgroup and in the p53-mutated subgroup. In addition we
will compare the PFS of patients who received treatment A
with the PFS of patients who received treatment B
independent of the p53 status. The secondary endpoints
are distant metastasis-free survival, overall survival and
toxicity. In total, 1440 patients will be included in this study
(including 10% of ineligible or nonassessable cases). We
have already included 960 patients.
An intermediate analysis is planned when all the patients
will be included in the study (number of expected events,
158). This analysis will provide some information
concerning the p53-mutated subgroup (80% power to
see an increase in the PFS of 30% in arm A to 50% in arm
B; hazard ratio, 1.76; alpha, 0.008), but it will be too soon
to obtain on the normal p53 subgroup.
If the recruitment in this study is performed over a period of
3 years, three additional years will be necessary before the
final analysis. There are no early stopping rules in this trial.
The primary endpoint of this trial is a translational research
question: do p53-mutated tumours respond better to
taxanes than p53 wild-type tumours? A frozen tumour
sample is mandatory before entering a patient in this trial.
We will therefore have ideal conditions to perform
translational research studies. For example, we are trying
to identify a cDNA microarray profile that can predict for a
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Figure 2
Treatment scheme of the European Organization for Research and Treatment of Cancer (EORTC) 10994 p53 trial. * Each collaborating group will
choose one of these two options before entering the patients into the trial. Arm A: FEC 100 (EORTC, Anglo-Celtic and SAKK [Swiss Group for
Clinical Research] groups), 500 mg/m2 fluorouracil, 100 mg/m2 epirubicin, 500 mg/m2 cyclophosphamide every 3 weeks for six cycles [12]; or
tailored FEC (Swedish group), all patients will start at the first course on day 1 with 600 mg/m2 fluorouracil intravenously (IV) on day 1, 75 mg/m2
epirubicin IV on day 1, 900 mg/m2 cyclophosphamide IV on day 1 every 3 weeks for six cycles; 5 µg/kg granulocyte-colony stimulating factor (G-
CSF) on days 5–12 and 500 mg ciprofloxacin orally twice daily on days 5–15 [13]. Arm B: 100 mg/m2 docetaxel every 3 weeks for three cycles,
followed by 90 mg/m2 epirubicin and 75 mg/m2 docetaxel every 3 weeks without G-CSF for three cycles. ** In case of progressive disease (PD)
after a minimum of two cycles, the patient will be off study. *** Locoregional treatment and hormonotherapy: in the absence of locoregional
progression, surgical and radiation therapy treatment will be planned according to the guidelines detailed in the full protocol. Tamoxifen (20 mg/day
for 5 years) will be prescribed at the end of neoadjuvant chemotherapy in patients with estrogen receptor-positive and/or progesterone receptor-
positive tumours. RAND, randomization.
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complete pathological response after treatment A
(anthracycline based) or treatment B (taxane based).
More detailed information is available online (www.eortc.be).
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